Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash & Equivalents (2016 - 2025)

Assembly Biosciences has reported Cash & Equivalents over the past 11 years, most recently at $58.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $58.4 million for Q4 2025, up 52.44% from a year ago — trailing twelve months through Dec 2025 was $58.4 million (up 52.44% YoY), and the annual figure for FY2025 was $58.4 million, up 52.44%.
  • Cash & Equivalents for Q4 2025 was $58.4 million at Assembly Biosciences, up from $22.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ASMB hit a ceiling of $78.3 million in Q1 2021 and a floor of $18.7 million in Q1 2024.
  • Median Cash & Equivalents over the past 5 years was $40.7 million (2022), compared with a mean of $40.0 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 62.15% in 2023 and later soared 93.26% in 2024.
  • Assembly Biosciences' Cash & Equivalents stood at $45.6 million in 2021, then increased by 14.88% to $52.4 million in 2022, then tumbled by 62.15% to $19.8 million in 2023, then soared by 93.26% to $38.3 million in 2024, then skyrocketed by 52.44% to $58.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $58.4 million (Q4 2025), $22.5 million (Q3 2025), and $24.0 million (Q2 2025) per Business Quant data.